| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
|
N Engl J Med
|
2004
|
41.02
|
|
2
|
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2006
|
16.25
|
|
3
|
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
|
JAMA
|
2006
|
11.22
|
|
4
|
Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
|
J Natl Cancer Inst
|
2005
|
7.70
|
|
5
|
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2003
|
6.57
|
|
6
|
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
|
Cancer Prev Res (Phila)
|
2010
|
5.81
|
|
7
|
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2006
|
4.99
|
|
8
|
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
|
J Clin Oncol
|
2005
|
4.66
|
|
9
|
Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27.
|
J Clin Oncol
|
2012
|
4.33
|
|
10
|
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
|
J Natl Cancer Inst
|
2002
|
3.99
|
|
11
|
Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer.
|
J Clin Oncol
|
2009
|
3.99
|
|
12
|
Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less.
|
J Clin Oncol
|
2002
|
3.82
|
|
13
|
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
J Clin Oncol
|
2010
|
3.79
|
|
14
|
Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data.
|
Lancet
|
2013
|
3.31
|
|
15
|
Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
|
J Natl Cancer Inst
|
2004
|
2.65
|
|
16
|
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
|
J Clin Oncol
|
2008
|
2.55
|
|
17
|
Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
|
JAMA
|
2006
|
2.38
|
|
18
|
Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.
|
J Clin Oncol
|
2012
|
2.34
|
|
19
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.
|
J Natl Cancer Inst
|
2013
|
2.28
|
|
20
|
Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.
|
J Clin Oncol
|
2005
|
2.17
|
|
21
|
Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20.
|
Breast Cancer Res Treat
|
2011
|
2.08
|
|
22
|
Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial.
|
Am J Obstet Gynecol
|
2005
|
1.83
|
|
23
|
Association of tamoxifen and uterine sarcoma.
|
J Clin Oncol
|
2002
|
1.80
|
|
24
|
Body mass index and the risk for developing invasive breast cancer among high-risk women in NSABP P-1 and STAR breast cancer prevention trials.
|
Cancer Prev Res (Phila)
|
2012
|
1.63
|
|
25
|
Prevention of hormone-related cancers: breast cancer.
|
J Clin Oncol
|
2005
|
1.62
|
|
26
|
Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer.
|
Breast Cancer Res Treat
|
2005
|
1.51
|
|
27
|
Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR).
|
Am J Obstet Gynecol
|
2011
|
1.48
|
|
28
|
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer.
|
Breast Cancer Res Treat
|
2008
|
1.41
|
|
29
|
Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer.
|
J Clin Oncol
|
2011
|
1.32
|
|
30
|
Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1).
|
J Natl Cancer Inst
|
2006
|
1.27
|
|
31
|
Lower-category benign breast disease and the risk of invasive breast cancer.
|
J Natl Cancer Inst
|
2004
|
1.19
|
|
32
|
Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial.
|
Cancer Prev Res (Phila)
|
2011
|
1.19
|
|
33
|
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention.
|
Cancer Discov
|
2013
|
1.12
|
|
34
|
Using the gene ontology to scan multilevel gene sets for associations in genome wide association studies.
|
Genet Epidemiol
|
2011
|
1.06
|
|
35
|
Pathologic variables predictive of breast events in patients with ductal carcinoma in situ.
|
Am J Clin Pathol
|
2007
|
1.06
|
|
36
|
Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group.
|
J Cancer Surviv
|
2009
|
1.04
|
|
37
|
Effect of Factor V Leiden and prothrombin G20210-->A mutations on thromboembolic risk in the national surgical adjuvant breast and bowel project breast cancer prevention trial.
|
J Natl Cancer Inst
|
2006
|
1.03
|
|
38
|
Effect of tamoxifen on venous thrombosis risk factors in women without cancer: the Breast Cancer Prevention Trial.
|
Br J Haematol
|
2003
|
1.00
|
|
39
|
Menstrual cycle and surgical treatment of breast cancer: findings from the NCCTG N9431 study.
|
J Clin Oncol
|
2009
|
0.99
|
|
40
|
Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.
|
J Natl Cancer Inst
|
2013
|
0.99
|
|
41
|
Evaluation of CYP2D6 and efficacy of tamoxifen and raloxifene in women treated for breast cancer chemoprevention: results from the NSABP P1 and P2 clinical trials.
|
Clin Cancer Res
|
2011
|
0.98
|
|
42
|
Effects of tamoxifen on benign breast disease in women at high risk for breast cancer.
|
J Natl Cancer Inst
|
2003
|
0.98
|
|
43
|
Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene.
|
Breast Cancer Res Treat
|
2012
|
0.96
|
|
44
|
National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene trial: advancing the science of recruitment and breast cancer risk assessment in minority communities.
|
Clin Trials
|
2013
|
0.91
|
|
45
|
Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01.
|
J Clin Oncol
|
2010
|
0.89
|
|
46
|
National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ.
|
Clin Cancer Res
|
2003
|
0.87
|
|
47
|
The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial.
|
Clin Breast Cancer
|
2002
|
0.86
|
|
48
|
Identification of accrual barriers onto breast cancer prevention clinical trials: a case-control study.
|
Cancer
|
2010
|
0.86
|
|
49
|
Cigarette smoking, physical activity, and alcohol consumption as predictors of cancer incidence among women at high risk of breast cancer in the NSABP P-1 trial.
|
Cancer Epidemiol Biomarkers Prev
|
2014
|
0.84
|
|
50
|
Re: tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.
|
J Natl Cancer Inst
|
2002
|
0.82
|
|
51
|
Contralateral breast cancer and thromboembolic events in African American women treated with tamoxifen.
|
J Natl Cancer Inst
|
2004
|
0.81
|
|
52
|
Baseline mammographic breast density and the risk of invasive breast cancer in postmenopausal women participating in the NSABP study of tamoxifen and raloxifene (STAR).
|
Cancer Prev Res (Phila)
|
2012
|
0.79
|
|
53
|
Carcinoma in situ outcomes in National Surgical Adjuvant Breast and Bowel Project Breast Cancer Chemoprevention Trials.
|
J Natl Cancer Inst Monogr
|
2010
|
0.79
|
|
54
|
A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.
|
Breast Cancer Res Treat
|
2015
|
0.78
|
|
55
|
Breast cancer chemoprevention: the saga of underuse continues.
|
J Natl Cancer Inst
|
2014
|
0.78
|
|
56
|
Is tamoxifen a risk factor for retinal vaso-occlusive disease?
|
Retina
|
2005
|
0.76
|